Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This trial aims to explore whether the intraoperative use of remimazolam can reduce the
incidence of postoperative nausea and vomiting (PONV) in high-risk patients. According to the
Apfel's simplified score, patients with 3 or more of the following factors are at high risk
of postoperative nausea and vomiting (PONV), i.e., women, non-smokers, history of PONV, and
postoperative use of opioids.